{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:03:33Z","timestamp":1772456613855,"version":"3.50.1"},"reference-count":39,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2021.12843","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T18:34:14Z","timestamp":1622658854000},"source":"Crossref","is-referenced-by-count":7,"title":["Treatment with lentiviral vectors encoding shRNA against interleukin 10 modulates the immunosuppressive activity of murine colon carcinoma\u2011associated myeloid\u2011derived suppressor cells"],"prefix":"10.3892","volume":"22","author":[{"given":"Natalia","family":"Anger\u2011g\u00f3ra","sequence":"first","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53\u2011114 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"W\u0119gierek\u2011Ciura","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53\u2011114 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Szczygie\u0142","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53\u2011114 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagoda","family":"Mierzejewska","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53\u2011114 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Pajtasz\u2011Piasecka","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53\u2011114 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Rossowska","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53\u2011114 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"key20210727105731_b1-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.3390\/ijms20174320","article-title":"The janus face of tumor microenvironment targeted by immunotherapy","volume":"20","author":"Buoncervello","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20210727105731_b2-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann Oncol"},{"key":"key20210727105731_b3-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"key20210727105731_b4-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"key20210727105731_b5-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","article-title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","volume":"5","author":"Gnjatic","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key20210727105731_b6-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1200\/EDBK_160766","article-title":"Biomarkers for immunotherapy: Current developments and challenges","volume":"35","author":"Spencer","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20210727105731_b7-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: Volume I-pre-analytical and analytical validation","volume":"4","author":"Masucci","year":"2016","journal-title":"J Immunother Cancer"},{"key":"key20210727105731_b8-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.5604\/01.3001.0012.8267","article-title":"Myeloid-derived suppressor cells as a target for anticancer therapy","volume":"72","author":"Anger","year":"2018","journal-title":"Post\u0119py Higieny i Medycyny Do\u015bwiadczalnej"},{"key":"key20210727105731_b9-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1038\/bcj.2015.56","article-title":"IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low\/-) monocytes in B-cell non-Hodgkin lymphoma","volume":"5","author":"Xiu","year":"2015","journal-title":"Blood Cancer J"},{"key":"key20210727105731_b10-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"76843","DOI":"10.18632\/oncotarget.20164","article-title":"Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells in ovarian cancer patients","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"key20210727105731_b11-ol-0-0-12843","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.159.10.4772","article-title":"Induction of tolerance by IL-10-treated dendritic cells","volume":"159","author":"Steinbrink","year":"1997","journal-title":"J Immunol"},{"key":"key20210727105731_b12-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1523-1747.2000.00881.x","article-title":"Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses","volume":"114","author":"Cavani","year":"2000","journal-title":"J Invest Dermatol"},{"key":"key20210727105731_b13-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"762","DOI":"10.4049\/jimmunol.164.2.762","article-title":"Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages","volume":"164","author":"Sica","year":"2000","journal-title":"J Immunol"},{"key":"key20210727105731_b14-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","article-title":"Current status of interleukin-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"key20210727105731_b15-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1084\/jem.170.6.2081","article-title":"Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones","volume":"170","author":"Fiorentino","year":"1989","journal-title":"J Exp Med"},{"key":"key20210727105731_b16-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","article-title":"Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy","volume":"51","author":"Sato","year":"2011","journal-title":"Immunol Res"},{"key":"key20210727105731_b17-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-018-0799-y","article-title":"Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy","volume":"37","author":"Rossowska","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"key20210727105731_b18-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"Sistigu","year":"2011","journal-title":"Semin Immunopathol"},{"key":"key20210727105731_b19-ol-0-0-12843","first-page":"7","article-title":"Loss of tumorigenicity of murine colon carcinoma MC38\/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes","volume":"50","author":"Pajtasz-Piasecka","year":"2004","journal-title":"Folia Biol (Praha)"},{"key":"key20210727105731_b20-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/CJI.0000000000000054","article-title":"Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number","volume":"37","author":"Rossowska","year":"2014","journal-title":"J Immunother"},{"key":"key20210727105731_b21-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fimmu.2017.00713","article-title":"Intratumoral lentivector-mediated TGF-\u03b21 gene downregulation as a potent strategy for enhancing the antitumor effect of therapy composed of cyclophosphamide and dendritic cells","volume":"8","author":"Rossowska","year":"2017","journal-title":"Front Immunol"},{"key":"key20210727105731_b22-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1128\/JVI.00014-10","article-title":"HIV-1 Lentiviral vector immunogenicity is mediated by toll-like receptor 3 (TLR3) and TLR7","volume":"84","author":"Breckpot","year":"2010","journal-title":"J Virol"},{"key":"key20210727105731_b23-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1158\/0008-5472.CAN-10-4627","article-title":"Interleukin (IL)-10 ablation promotes tumor development, growth and metastasis","volume":"72","author":"Tanikawa","year":"2012","journal-title":"Cancer Res"},{"key":"key20210727105731_b24-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"key20210727105731_b25-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2174\/156652308786848058","article-title":"Lentiviral vectors for anti-tumor immunotherapy","volume":"8","author":"Breckpot","year":"2008","journal-title":"Curr Gene Ther"},{"key":"key20210727105731_b26-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.4049\/jimmunol.0903062","article-title":"The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors","volume":"184","author":"Furmanov","year":"2010","journal-title":"J Immunol"},{"key":"key20210727105731_b27-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s11262-017-1495-2","article-title":"Reconstructing the immune system with lentiviral vectors","volume":"53","author":"Olbrich","year":"2017","journal-title":"Virus Genes"},{"key":"key20210727105731_b28-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"key20210727105731_b29-ol-0-0-12843","doi-asserted-by":"publisher","DOI":"10.1002\/9780470688618.taw0220","article-title":"The Immune response to viral infections","author":"Nash","year":"2010","journal-title":"Topley & Wilson's Microbiology and Microbial Infections"},{"key":"key20210727105731_b30-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"e1518672","DOI":"10.1080\/2162402X.2018.1518672","article-title":"Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression","volume":"8","author":"Tan","year":"2019","journal-title":"Oncoimmunology"},{"key":"key20210727105731_b31-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.imbio.2014.10.009","article-title":"Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response","volume":"220","author":"Rossowska","year":"2015","journal-title":"Immunobiology"},{"key":"key20210727105731_b32-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1158\/2326-6066.CIR-16-0048","article-title":"Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed","volume":"4","author":"Abu Eid","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"key20210727105731_b33-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/gastro\/goz060","article-title":"Antitumor immunity of low-dose cyclophosphamide: Changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis","volume":"8","author":"Huang","year":"2019","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"key20210727105731_b34-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1567-5769(00)00028-X","article-title":"Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response","volume":"1","author":"Matar","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"key20210727105731_b35-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1016\/j.vaccine.2016.07.054","article-title":"Enhancement of fibroblast activation protein \u03b1-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice","volume":"34","author":"Xia","year":"2016","journal-title":"Vaccine"},{"key":"key20210727105731_b36-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"1703449","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: Chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"Oncoimmunology"},{"key":"key20210727105731_b37-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res"},{"key":"key20210727105731_b38-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1189\/jlb.0813435","article-title":"DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment","volume":"95","author":"Miky\u0161kov\u00e1","year":"2014","journal-title":"J Leukoc Biol"},{"key":"key20210727105731_b39-ol-0-0-12843","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/jid.2012.444","article-title":"Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma","volume":"133","author":"Sevko","year":"2013","journal-title":"J Invest Dermatol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T12:28:51Z","timestamp":1699100931000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2021.12843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,2]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2021.12843","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"article-number":"582"}}